{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T07:15:30Z","timestamp":1772003730336,"version":"3.50.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.1016\/j.neuropharm.2009.10.004","type":"journal-article","created":{"date-parts":[[2009,10,23]],"date-time":"2009-10-23T04:44:19Z","timestamp":1256273059000},"page":"357-364","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Discriminative stimulus effects of L-838,417 (7-tert-butyl-3-(2,5-difluoro-phenyl)-6-(2-methyl-2H-[1,2,4]triazol-3-ylmethoxy)-[1,2,4]triazolo[4,3-b]pyridazine): Role of GABAA receptor subtypes"],"prefix":"10.1016","volume":"58","author":[{"given":"Stephanie C.","family":"Licata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donna M.","family":"Platt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"R\u00fcedi-Bettschen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John R.","family":"Atack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerard R.","family":"Dawson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael L.","family":"Van Linn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James M.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James K.","family":"Rowlett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2009.10.004_bib1","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/sj.bjp.0706056","article-title":"Anxiogenic properties of an inverse agonist selective for alpha3 subunit-containing GABA A receptors","volume":"144","author":"Atack","year":"2005","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2009.10.004_bib3","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1017\/S1092852900009883","article-title":"Contributions of GABAA receptor subtype selectivity to abuse liability and dependence potential of pharmacological treatments for anxiety and sleep disorders","volume":"10","author":"Ator","year":"2005","journal-title":"CNS Spectr."},{"key":"10.1016\/j.neuropharm.2009.10.004_bib4","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/ddr.430160229","article-title":"Asymmetrical cross-generalization with lorazepam and pentobarbital training conditions","volume":"16","author":"Ator","year":"1989","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.neuropharm.2009.10.004_bib5","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1021\/jm0110789","article-title":"3-Heteroaryl-2-pyridones: benzodiazepine site ligands with functional selectivity for \u03b12\/\u03b13-subtypes of human GABAA receptor-ion channels","volume":"45","author":"Collins","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2009.10.004_bib7","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1097\/01.alc.0000175073.94575.86","article-title":"Selective GABAA alpha5 benzodiazepine inverse agonist antagonizes the neurobehavioral actions of alcohol","volume":"29","author":"Cook","year":"2005","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.neuropharm.2009.10.004_bib8","doi-asserted-by":"crossref","first-page":"10682","DOI":"10.1523\/JNEUROSCI.1166-05.2005","article-title":"Evidence for a significant role of \u03b13-containing GABAA receptors in mediating the anxiolytic effects of benzodiazepines","volume":"46","author":"Dias","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2009.10.004_bib9","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/S0022-3565(25)11125-7","article-title":"Relationship between benzodiazepine receptor occupancy and potentiation of gamma-aminobutyric acid-stimulated chloride flux in vitro of four ligands of differing intrinsic efficacies","volume":"261","author":"Facklam","year":"1992","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"Suppl. 2","key":"10.1016\/j.neuropharm.2009.10.004_bib11","first-page":"25","article-title":"The preclinical pharmacology of flumazenil","author":"Haefely","year":"1988","journal-title":"Eur. J. Anaesthesiol."},{"key":"10.1016\/j.neuropharm.2009.10.004_bib12","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.pbb.2008.02.019","article-title":"Novel discriminative stimulus effects of TPA023B, a subtype-selective \u03b3-aminobutyric-acidA\/benzodiazepine modulator: comparisons with zolpidem, lorazepam, and TPA023","volume":"90","author":"Kohut","year":"2008","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2009.10.004_bib13","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3109\/07853899708999348","article-title":"GABAA-receptor subtypes: clinical efficacy and selectivity of benzodiazepine site ligands","volume":"29","author":"Korpi","year":"1997","journal-title":"Ann. Med."},{"key":"10.1016\/j.neuropharm.2009.10.004_bib15","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/S0022-3565(24)39151-7","article-title":"Antagonism of the discriminative stimulus effects of positive gamma-aminobutyric acid(A) modulators in rhesus monkeys discriminating midazolam","volume":"294","author":"Lelas","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2009.10.004_bib16","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1037\/1064-1297.8.3.294","article-title":"Using behavior to elucidate receptor mechanisms: a review of the discriminative stimulus effects of benzodiazepines","volume":"8","author":"Lelas","year":"2000","journal-title":"Exp. Clin. Psychopharm."},{"key":"10.1016\/j.neuropharm.2009.10.004_bib17","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s002130000615","article-title":"Triazolam discrimination in squirrel monkeys distinguishes high-efficacy agonists from other benzodiazepines and non-benzodiazepine drugs","volume":"154","author":"Lelas","year":"2001","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2009.10.004_bib19","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s00213-002-1037-y","article-title":"Role of GABAA\/benzodiazepine receptors containing \u03b11 and \u03b15 subunits in the discriminative stimulus effects of triazolam in squirrel monkeys","volume":"161","author":"Lelas","year":"2002","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2009.10.004_bib39","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.pbb.2008.01.001","article-title":"Abuse and dependence liability of benzodiazepine-type drugs: GABAA receptor modulation and beyond","volume":"90","author":"Licata","year":"2008","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2009.10.004_bib20","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1126\/science.290.5489.131","article-title":"Molecular and neuronal substrate for the selective attenuation of anxiety","volume":"290","author":"L\u00f6w","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2009.10.004_bib21","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/75761","article-title":"Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABAA receptor alpha1 subtype","volume":"3","author":"McKernan","year":"2000","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2009.10.004_bib22","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/sj.bjp.0706550","article-title":"Differential behavioral effects of low efficacy positive GABAA modulators in combination with benzodiazepines and a neuroactive steroid in rhesus monkeys","volume":"147","author":"McMahon","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2009.10.004_bib23","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1124\/jpet.105.094003","article-title":"Comparative cue generalization profiles of L-838,417, SL651498, zolpidem, CL218872, ocinaplon, bretazenil, zopiclone, and various benzodiazepines in chlordiazepoxide and zolpidem drug discrimination","volume":"316","author":"Mirza","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2009.10.004_bib24","series-title":"Current Protocols in Pharmacology","first-page":"9.21.1.1","article-title":"Intravenous self-administration techniques in monkeys","author":"Platt","year":"2005"},{"key":"10.1016\/j.neuropharm.2009.10.004_bib25","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1124\/jpet.104.080275","article-title":"Contribution of \u03b11GABAA and \u03b15GABAA receptor subtypes to the discriminative stimulus effects of ethanol in squirrel monkeys","volume":"313","author":"Platt","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2009.10.004_bib26","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S0022-3565(24)35232-2","article-title":"Discriminative stimulus effects of zolpidem in squirrel monkeys: comparison with conventional benzodiazepines and sedative-hypnotics","volume":"291","author":"Rowlett","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2009.10.004_bib27","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0014-2999(00)00669-5","article-title":"Transduction of the discriminative stimulus effects of zolpidem by GABAA\/\u03b11 receptors","volume":"406","author":"Rowlett","year":"2000","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2009.10.004_bib28","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s00213-002-1275-z","article-title":"Discriminative stimulus effects of zolpidem in squirrel monkeys: role of GABAA\/\u03b11 receptors","volume":"165","author":"Rowlett","year":"2003","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2009.10.004_bib29","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1073\/pnas.0405621102","article-title":"Different GABAA receptor subtypes mediate the anxiolytic, abuse-related, and motor effects of benzodiazepine-like drugs in primates","volume":"102","author":"Rowlett","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2009.10.004_bib30","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00213-005-0228-8","article-title":"Anti-conflict effects of benzodiazepines in rhesus monkeys: relationship with therapeutic doses in humans and role of GABAA receptors","volume":"184","author":"Rowlett","year":"2006","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2009.10.004_bib31","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/44579","article-title":"Benzodiazepine actions mediated by specific\u00a0gamma-aminobutyric acid(A) receptor subtypes","volume":"401","author":"Rudolph","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2009.10.004_bib32","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/S0165-6147(00)01646-1","article-title":"GABAA receptor subtypes: dissecting their pharmacological functions","volume":"22","author":"Rudolph","year":"2001","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2009.10.004_bib33","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1037\/1064-1297.8.1.22","article-title":"Discriminative-stimulus effects of zolpidem, triazolam, pentobarbital, and caffeine in zolpidem-trained humans","volume":"8","author":"Rush","year":"2000","journal-title":"Exp. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2009.10.004_bib34","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0022-3565(25)21015-1","article-title":"Beta-carbolines as antagonists of the discriminative stimulus effects of diazepam in rats","volume":"246","author":"Shannon","year":"1988","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2009.10.004_bib35","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/S0022-3565(25)23951-9","article-title":"Discriminative-stimulus effects of midazolam in squirrel monkeys: comparison with other drugs and antagonism by Ro 15-1788","volume":"235","author":"Spealman","year":"1985","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2009.10.004_bib36","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S0893-133X(02)00310-X","article-title":"Effects of alprazolam on driving ability, memory functioning and psychomotor performance: a randomized, placebo-controlled study","volume":"27","author":"Verster","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2009.10.004_bib38","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1023\/A:1021674708556","article-title":"Effect of flumazenil on GABAA receptors in isolated rat hippocampal neurons","volume":"27","author":"Weiss","year":"2002","journal-title":"Neurochem. Res."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390809003323?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390809003323?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T06:40:12Z","timestamp":1758436812000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390809003323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["S0028390809003323"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2009.10.004","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2010,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discriminative stimulus effects of L-838,417 (7-tert-butyl-3-(2,5-difluoro-phenyl)-6-(2-methyl-2H-[1,2,4]triazol-3-ylmethoxy)-[1,2,4]triazolo[4,3-b]pyridazine): Role of GABAA receptor subtypes","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2009.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}